MONOPAR THERAPEUTICS INC (MNPR) Fundamental Analysis & Valuation

NASDAQ:MNPR • US61023L2079

Current stock price

55.39 USD
+0.6 (+1.1%)
At close:
55.39 USD
0 (0%)
After Hours:

This MNPR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MNPR Profitability Analysis

1.1 Basic Checks

  • In the past year MNPR has reported negative net income.
  • In the past year MNPR has reported a negative cash flow from operations.
  • In the past 5 years MNPR always reported negative net income.
  • In the past 5 years MNPR always reported negative operating cash flow.
MNPR Yearly Net Income VS EBIT VS OCF VS FCFMNPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of MNPR (-9.75%) is better than 82.79% of its industry peers.
  • Looking at the Return On Equity, with a value of -9.95%, MNPR belongs to the top of the industry, outperforming 86.07% of the companies in the same industry.
Industry RankSector Rank
ROA -9.75%
ROE -9.95%
ROIC N/A
ROA(3y)-50%
ROA(5y)-54.77%
ROE(3y)-62.88%
ROE(5y)-68.19%
ROIC(3y)N/A
ROIC(5y)N/A
MNPR Yearly ROA, ROE, ROICMNPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MNPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNPR Yearly Profit, Operating, Gross MarginsMNPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. MNPR Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for MNPR has been increased compared to 1 year ago.
  • Compared to 5 years ago, MNPR has less shares outstanding
  • MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MNPR Yearly Shares OutstandingMNPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
MNPR Yearly Total Debt VS Total AssetsMNPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • MNPR has an Altman-Z score of 76.70. This indicates that MNPR is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 76.70, MNPR belongs to the best of the industry, outperforming 97.68% of the companies in the same industry.
  • MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 76.7
ROIC/WACCN/A
WACCN/A
MNPR Yearly LT Debt VS Equity VS FCFMNPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 51.35 indicates that MNPR has no problem at all paying its short term obligations.
  • MNPR has a Current ratio of 51.35. This is amongst the best in the industry. MNPR outperforms 99.42% of its industry peers.
  • A Quick Ratio of 51.35 indicates that MNPR has no problem at all paying its short term obligations.
  • MNPR's Quick ratio of 51.35 is amongst the best of the industry. MNPR outperforms 99.42% of its industry peers.
Industry RankSector Rank
Current Ratio 51.35
Quick Ratio 51.35
MNPR Yearly Current Assets VS Current LiabilitesMNPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MNPR Growth Analysis

3.1 Past

  • MNPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.47%, which is quite impressive.
EPS 1Y (TTM)49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MNPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.30% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-107.13%
EPS Next 2Y-48.73%
EPS Next 3Y-15.2%
EPS Next 5Y30.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNPR Yearly Revenue VS EstimatesMNPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
MNPR Yearly EPS VS EstimatesMNPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. MNPR Valuation Analysis

4.1 Price/Earnings Ratio

  • MNPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNPR Price Earnings VS Forward Price EarningsMNPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNPR Per share dataMNPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • A cheap valuation may be justified as MNPR's earnings are expected to decrease with -15.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.73%
EPS Next 3Y-15.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MNPR Dividend Analysis

5.1 Amount

  • MNPR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MNPR Fundamentals: All Metrics, Ratios and Statistics

MONOPAR THERAPEUTICS INC

NASDAQ:MNPR (4/1/2026, 8:00:01 PM)

After market: 55.39 0 (0%)

55.39

+0.6 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-11
Inst Owners82.83%
Inst Owner Change25.28%
Ins Owners6.73%
Ins Owner Change4.43%
Market Cap370.01M
Revenue(TTM)N/A
Net Income(TTM)-13.72M
Analysts84
Price Target114.24 (106.25%)
Short Float %32.42%
Short Ratio7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.68
P/tB 2.68
EV/EBITDA N/A
EPS(TTM)-1.82
EYN/A
EPS(NY)-3.63
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS0
BVpS20.63
TBVpS20.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.75%
ROE -9.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50%
ROA(5y)-54.77%
ROE(3y)-62.88%
ROE(5y)-68.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 51.35
Quick Ratio 51.35
Altman-Z 76.7
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.65%
EPS Next Y-107.13%
EPS Next 2Y-48.73%
EPS Next 3Y-15.2%
EPS Next 5Y30.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-179.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-90.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.52%
OCF growth 3YN/A
OCF growth 5YN/A

MONOPAR THERAPEUTICS INC / MNPR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MONOPAR THERAPEUTICS INC (MNPR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MNPR.


What is the valuation status of MONOPAR THERAPEUTICS INC (MNPR) stock?

ChartMill assigns a valuation rating of 0 / 10 to MONOPAR THERAPEUTICS INC (MNPR). This can be considered as Overvalued.


How profitable is MONOPAR THERAPEUTICS INC (MNPR) stock?

MONOPAR THERAPEUTICS INC (MNPR) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MONOPAR THERAPEUTICS INC?

The Earnings per Share (EPS) of MONOPAR THERAPEUTICS INC (MNPR) is expected to decline by -107.13% in the next year.